MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency

Stock Information for MeiraGTx Holdings plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MeiraGTx Holdings plc

MeiraGTx to Participate in Upcoming Investor Conferences
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
MeiraGTx to Participate in Upcoming Investor Conferences
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.